TP53 and neoplasm: Two predicted DUBs (USP11 and USP20) for FOXP3, along with two predicted substrates (Androgen receptor AR and Cellular tumor antigen p53) for USP22 were validated by our “wet lab” experiments, contributing to tumor immune escape-related drug target discovery and precise application of anti-tumor agent, respectively.